News and Trends 9 Jun 2023 Med-Life Discoveries to start rare pediatric disease trial Med-Life Discoveries, LP (MLD) is a Canadian biopharmaceutical company dedicated to advancing a therapy to reduce symptoms for a devastating pediatric rare disease, Rhizomelic chondrodysplasia punctata (RCDP), which causes significant physical and neurological delays in children who inherit it. Med-Life Discoveries has received a no objection letter (NOL) from Health Canada to begin a phase […] June 9, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2023 MOSAIC spatial atlas of cancer cells to be created Owkin, NanoString Technologies and cancer research institutions University of Pittsburgh, Gustave Roussy, Lausanne University Hospital, Uniklinikum Erlangen/Friedrich-Alexander- Universität Erlangen-Nürnberg, and Charité – Universitätsmedizin Berlin are launching MOSAIC (Multi Omic Spatial Atlas In Cancer) at the American Society of Clinical Oncology’s annual meeting. MOSAIC is a $50 million project to revolutionize cancer research through the use […] June 9, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2023 Astellas developing new gastric cancer drug Astellas Pharma Inc. has submitted a new drug application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for zolbetuximab. Zolbetuximab is a first-in-class investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive. If approved, […] June 9, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2023 Quell in potential $2B AstraZeneca cell therapy deal Quell Therapeutics Ltd, a developer of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has entered into a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture and commercialize autologous, engineered Treg cell therapies for two autoimmune disease indications. “We are extremely pleased to have AstraZeneca on […] June 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2023 Acepodia raises $100M financing to boost cell therapies Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its antibody-cell conjugation (ACC) and allogeneic gamma delta 2 T-cell platforms to address gaps in cancer care, has announced a $100 million Series D financing. The funds will be used to progress the company’s pipeline of enhanced cell therapies for solid tumors and hematologic […] June 8, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2023 Kate Therapeutics launches with $51M to develop genetic medicines for muscle and heart diseases Gene therapy company Kate Therapeutics Inc. (KateTx), has emerged from stealth mode with a $51 million Series A financing. In addition, the company has granted Astellas Pharma Inc. an exclusive, worldwide license to develop, manufacture and commercialize KT430 to treat X-linked myotubular myopathy (XLMTM). There are a large number of genetically defined and complex muscle […] June 8, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Jun 2023 Six companies that have made their name in the cardiovascular space Cardiovascular disease is a general term used to describe a disease that affects the heart and blood vessels. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, with statistics from 2019 stating that an estimated 17.9 million people died from some type of cardiovascular disease, making up 32% […] June 8, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2023 Minoryx can start phase 3 trial for cerebral adrenoleukodystrophy patients Spanish-headquartered Minoryx Therapeutics says the U.S. Food and Drug Administration (FDA) has approved its phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked adrenoleukodystrophy (X-ALD) patients with cerebral adrenoleukodystrophy (cALD). X-ALD is an orphan neurodegenerative disease. The global incidence of X-ALD is approximately six to eight per 100,000 live births. […] June 8, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 7 Jun 2023 How Ireland connects AI and life sciences Depending on your point of view, artificial intelligence (AI) can create jobs, make life easier, and solve many global problems; or, it’s going to cause mass unemployment, take over the world, and enslave humanity. In the life sciences space, AI is capable of tackling some of the biggest challenges when it comes to tasks like […] June 7, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2023 AAVantgarde closes €61M financing to move gene delivery program to the clinic AAVantgarde Bio, a clinical-stage, Italian-based international biotechnology company with two proprietary adeno-associated viral (AAV) vector platforms for large gene delivery, has closed a €61 million ($65.1 million) Series A financing. The amount represents the largest series A round ever in Italian biotech. AAVantgarde has two proprietary, AAV-based large gene delivery platforms: one leveraging DNA recombination, […] June 7, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 6 Jun 2023 $5.5M funding for Oncopole to tackle cancer Oncopole, Fonds de recherche du Québec – Santé (FRQS) cancer division in Canada, has received major investments that boost its public-private partnership model dedicated to the fight against cancer. Oncopole will continue to pursue its mission thanks to a $3 million reinvestment from founding partner Merck Canada. Oncopole, FRQS cancer division, is the result of […] June 6, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2023 Head and neck cancer data presented at ASCO 2023 Results from promising trials in the fight against head and neck cancer have been presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation, a provider of IT, network and AI technologies, announced new […] June 6, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email